Cascadian Therapeutics Inc (NASDAQ:CASC) has been given an average recommendation of “Hold” by the seven analysts that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $7.00.
Several brokerages recently issued reports on CASC. ValuEngine raised Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 31st. BidaskClub upgraded Cascadian Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 31st. Raymond James downgraded Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 31st. Finally, Cantor Fitzgerald set a $10.00 price target on Cascadian Therapeutics and gave the stock a “hold” rating in a report on Friday, March 9th.
Cascadian Therapeutics remained flat at $$10.02 during trading hours on Monday, Marketbeat reports. Cascadian Therapeutics has a fifty-two week low of $3.18 and a fifty-two week high of $10.21.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.